

Receipt date: 10/12/2011

12966240 - GAU: 3626

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number		12/966,240
				Filing Date		December 13, 2010
				First Named Inventor		Marc Elsayed
				Art Unit		3626
Examiner Name		Christopher L. Gilligan				
Sheet	1	of	7	Attorney Docket Number	CELG-0641	

U. S. PATENT APPLICATION DOCUMENTS				
Examiner Initials	Cite No.	Application Number	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1	09/479,682	01-07-2000	Elsayed

U. S. PUBLICATION AND PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication or Grant Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		Number - Kind Code (if known)			
	2	2006/0129433	06-15-2006	Koneru	
	3	5,299,121	03-20-1994	Brill, et al.	
	4	5,594,637	01-14-1997	Eisenberg, et al.	
	5	5,619,991	04-15-1997	Sloane	
	6	5,660,176	08-26-1997	Iliff	
	7	5,758,095	05-26-1998	Albaum et al.	
	8	5,832,449	11-03-1998	Cunningham	
	9	5,845,255	12-01-1998	Mayaud	
	10	6,014,631	01-11-2000	Teagarden et al.	
	11	6,055,507	04-25-2000	Cunningham	
	12	6,128,620	10-03-2000	Pissanos et al.	
	13	5,974,203	10-26-1999	Tadokoro et al.	
	14	6,045,501	04-04-2000	Elsayed et al.	
	15	6,063,026	05-16-2000	Schauss et al.	
	16	6,131,090	10-10-2000	Basso, Jr. et al.	
	17	6,202,923	03-20-2001	Bayer et al.	
	18	6,315,720	11-13-2001	Williams et al.	
	19	6,561,978	05-13-2003	Elsayed et al.	
	20	6,561,976	05-13-2003	Elsayed et al.	
	21	6,561,977	05-13-2003	Williams et al.	
Examiner Signature	/C. Luke Gilligan/			Date Considered	02/13/2012

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.L.G

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,240
				Filing Date	December 13, 2010
				First Named Inventor	Marc Elsayed
				Art Unit	3626
Examiner Name	Christopher L. Gilligan				
Sheet	2	of	7	Attorney Docket Number	CELG-0641

U. S. PUBLICATION AND PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number	Publication or Grant Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number - Kind Code (if known)		
	22	6,755,784	06-29-2004	Williams et al.
	23	6,767,326	07-27-2004	Elsayed et al.
	24	6,869,399	03-22-2005	Williams et al.
	25	6,908,432	06-21-2005	Elsayed et al.
	26	7,874,984	01-25-2011	Elsayed et al.

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T
		Country Code- Number - Kind Code (if known)			
	27	WO 96/13790	05-09-1996	Med-E-Systems Corp	
	28	WO 98/13783	04-02-1998	Azron, Inc.	
	29	WO 99/10829	03-04-1999	DEKA Products LP	
	30	WO 00/51053	08-31-2000	Gemini Research LTD.	
	31	WO 98/58338	12-23-1998	Promedicus Systems Inc.	
	32	WO 02/35440	05-02-2002	Celgene Corp	
	33	CA 2 352 619	01-06-2003	Tornado Technologies Inc.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.	T
	34	"About the CNR," Website Printout: https://www.clozarilcare.com/care/NewUsrReqPersonal.jsp	

Examiner Signature	/C. Luke Gilligan/	Date Considered	02/13/2012
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.L.G

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		12/966,240	
				Filing Date		December 13, 2010	
				First Named Inventor		Marc Elsayed	
				Art Unit		3626	
				Examiner Name		Christopher L. Gilligan	
Sheet	3	of	7	Attorney Docket Number	CELG-0641		

NON PATENT LITERATURE DOCUMENTS				
35		Bakken, K., et al., "Local monitoring center for clozapine therapy: quality assurance of drug treatment in a group of psychiatric patients," <i>Tidsskr Nor Laegeforen nr.</i> , 1998, 118, 1076 – 1078 (English abstract middle of page 1076)		
36		Bastani, B., et al., "Development of the clozaril patient management system," <i>Psychopharmacology</i> , 1989, 99, S122 – S125		
37		Bates, D. W. et al., "Effect of Computerized Physician Order Entry and a Team Intervention on Prevention of Serious Medication Errors," <i>JAMA</i> , October 21, 1998, 280(15), 1311-1316		
38		Behm, G.A., Jr., No Title, <i>Am. Pharmacy 13th APhA Annual Meeting Highlights</i> , 1990, NS30(6), page 7		
39		Bender, K.J., "FDA approves reduced clozapine monitoring; increased patient access versus increased risk," <i>Psychiatric Times</i> , 1998, Vol. XV, Issue 5, page 13		
40		Black, L.L., et al., "A centralized system for monitoring clozapine use in British Columbia," <i>Psychiatric Services</i> , 1996, 47(1), 81-83		
41		Bruera, E., and Neumann, C. M., "The uses of psychotropics in symptom management in advanced cancer," <i>Psycho-Oncology.</i> , 1998, 7, 346-358		
42		Clark, T. E., et al., "Thalidomide Capsules, A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing," <i>Drug Safety.</i> , 2001, 24(2), 87-117		
43		Complaint filed 1/18/2007 in NJ: <i>Celgene Corp. v. Barr Laboratories</i> , Case No. 2:07-cv-00286-PGS-RJH		
44		Defendant Barr Laboratories, Inc.'s Answer, Counterclaims and Demand for Jury Trial filed 3/01/2007 in NJ: <i>Celgene Corp. v. Barr Laboratories</i> , Case No. 2:07-cv-00286-PGS-RJH		
45		Dimopoulos, M. A., and Eleutherakis-Papaiakevou, V., "Adverse effects of Thalidomide administration in patients with neoplastic diseases," <i>Am. J. Med.</i> , October 1, 2004, 117, 508-515		
46		Fax sent 10/14/04 from Ian Hilley of GenPharm, Inc. to John Jackson of Celgene Corp. re: Isotretinoin Pregnancy Risk Management Program		
47		<i>FDA's Forty-Seventh Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee</i> , September 4-5, 1997		
48		Freeman, D.J., et al., "Will routine therapeutic drug monitoring have a place in clozapine therapy?," <i>Clinical Pharmacokinetics</i> , 1997, 32(2), 93-100		
Examiner Signature	/C. Luke Gilligan/		Date Considered	02/13/2012

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.L.G

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		12/966,240	
				Filing Date		December 13, 2010	
				First Named Inventor		Marc Elsayed	
				Art Unit		3626	
				Examiner Name		Christopher L. Gilligan	
Sheet	4	of	7	Attorney Docket Number	CELG-0641		

NON PATENT LITERATURE DOCUMENTS		
49	"Hoechst Arava Pregnancy Registry Recommended To Track Teratogenicity," <i>The Pink Sheet</i> , August 17, 1998, Vol. 60, Number 033, page 23	
50	Honigfeld, G., et al., "Reducing clozapine-related morbidity and mortality: 5 years of experience with the clozaril national registry," <i>J. Clin. Psychiatry</i> , 1998, 59(Suppl. 3), 3-7	
51	Honigfeld, G., "Effects Of The Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis," <i>Psychiatric Services</i> , January 1996, 47(1), 52-56	
52	Janet Woodcock, Director, Center for Drug Evaluation and Research, "Supervisory Review of NDA 20-785," July 7, 1998	
53	Kumar, V., "Clozaril monitoring systems, registry data and analyses," Presentation, <i>Novartis</i> , 2002, 44 pages	
54	Lieberman, J.A., et al., "A report of clozapine – induced agranulocytosis in the United States (Incidence and risk factors)," <i>Drug Safety, Proceedings of a symposium held in London</i> , 1991, Hoffbrand, A.V, et al. (Eds.), 1-2	
55	Love, D.J., et al., "Computerized relational database for monitoring clozapine therapy," <i>Am. J. Hosp. Pharm.</i> , 1993, 1657-1662	
56	Martin, S., "APhA says plan continues to interfere with pharmacists' practice prerogatives," <i>Am. Pharmacy</i> , 1991, NS31(5), 30-31	
57	<i>Medical Marketing & Media</i> , "Managing a product under attack: a firsthand report on Clozaril: Interview with Sandoz Ltd.'s director of product marketing, Barbara Rosengren and assistant director Gilbert Honigfeld," September 20, 1991, Vol. 26, No. 10, page 6	
58	Mitchell, A. A. et al., "A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin," <i>N. Engl. J. Med.</i> , July 13, 1995, 333(2), 101-106	
59	Mordue, H.W., "Rational approach to clozaril distribution," <i>Am. Pharmacy</i> , 1990, NS30(6), page 7	
60	Notification letter dated 12/5/06 from Sterne Kessler to Celgene Corporation re: Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
61	Notification letter dated 12/15/06 from Sterne Kessler to Celgene Corporation re: Supplemental Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	

Examiner Signature	/C. Luke Gilligan/	Date Considered	02/13/2012
---------------------------	--------------------	------------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.L.G

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	12/966,240
				Filing Date	December 13, 2010
				First Named Inventor	Marc Elsayed
				Art Unit	3626
				Examiner Name	Christopher L. Gilligan
Sheet	5	of	7	Attorney Docket Number	CELG-0641

NON PATENT LITERATURE DOCUMENTS		
62	Notification letter dated 12/19/06 from Sterne Kessler to Celgene Corporation re: Supplemental Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
63	Notification letter dated 10/04/2007 from Barr Laboratories to Celgene Corporation re: Supplemental Notification Pursuant to § 505(j)(2)(B)(ii) of the Federal Food, Drug and Cosmetic Act	
64	Oyesanmi, O., et al., "Hematologic side effects of psychotropics," <i>Psychosomatics</i> , 1999, 40, 414-421	
65	Pastuszak, A. et al., "Use Of The Retinoid Pregnancy Prevention Program In Canada: Patterns Of Contraception Use In Women Treated With Isotretinoin And Etretinate," <i>Reproductive Toxicology</i> , 1994, 8(1), 63-68	
66	Patt, Y.Z, et al., "Durable Clinical response of refractory hepatocellular to orally administered thalidomide," <i>Am. J. Clin. Oncol. (CCT.)</i> , 2000, 23(3), 319-321	
67	Peck, C.C., et al., "FDA's position on the clozaril patient management system," <i>Hospital & Community Psychiatry</i> , 1990, 41(8), 876-877	
68	Physician's Desk Reference, 1997, pp. 2252-2254, 2377-2380	
69	Press Release dated 11/23/04, "Isotretinoin Makers Reach Agreement with Celgene on S.T.E.P.S. Risk Management Patents,"	
70	Reference Guide "THALIDOMID™ (thalidomide): Clinical Information and Prescribing Guidelines," Celgene Corporation, 9/98	
71	Richardson, P, et al., "Thalidomide: Emerging role in cancer medicine," <i>Annu. Rev. Med.</i> , 2002, 53, 629-657	
72	Richardson, P., et al., "Thalidomide: The revival of a drug with Therapeutic promise in the treatment of cancer", In: <i>Cancer: Principles and Practice of Oncology</i> , 6 th Ed., DeVita VT, Hellman S, Rosenberg SA, editors. Lippincott, Williams, and Wilkins, Philadelphia PA, 2001, 1-18.	
73	Roche's Press Release Regarding Pregnancy Prevention Program for Women for Women on Accutane, October 31, 2001	
74	Singhal, S. and Mehta, J., "Peer Viewpoint," <i>J. Supportive Oncology</i> , 1(3), September/October 2003, 200-201	

Examiner Signature	/C. Luke Gilligan/	Date Considered	02/13/2012
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.L.G

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.